Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 S252W |
| Therapy | Fexagratinib |
| Indication/Tumor Type | endometrial cancer |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 S252W | endometrial cancer | decreased response | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, endometrial cells harboring Fgfr2 S252W were less sensitive to the anti-proliferative effects of Fexagratinib (AZD4547) than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741). | 26294741 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26294741) | Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells. | Full reference... |